查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511801

mRNA 治疗药物合约开发和製造组织 (CDMO) 的市场规模、份额和趋势分析报告：按应用、按适应症、按最终用途、按地区和细分市场预测，2024-2030 年

mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 144 Pages | 商品交期: 2-10个工作天内

价格

mRNA 疗法合约开发和製造组织 (CDMO) 市场的成长和趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球mRNA疗法合约开发和製造机构市场规模将达到83.5亿美元，2024年至2030年复合年增长率为11.28%。

mRNA 和细胞递送系统技术的不断进步，加上其成本效益、易于製造以及针对以前无法治疗的途径的能力，为医学革命提供了无限的潜力。这对市场来说可能是一个利润丰厚的成长机会。增加研发投资和强大的产品平臺来开发 mRNA 疗法也正在推动市场成长。例如，Moderna宣布其2023年第四季研发费用达14亿美元，较2022年同期成长16%。

研发费用是由于该公司巨细胞病毒（CMV）疫苗、RSV疫苗、COVID-19和流感联合疫苗以及个人化新抗原治疗的临床生产活动增加而推动的。这些因素预计将推动 mRNA 疗法的研究工作。此外，为解决未满足的医疗需求而开拓新的治疗剂正在改变产品市场。随着分子复杂性的增加，人们越来越需要研究和製造服务的深入知识，以及永续新型分子形式的可持续表达和规模化的技术。生物偶联和双特异性抗体生成等平台技术可以显着缩短开发和生产时间，从而使客户能够加快上市时间并降低投资风险。因此，CDMO 为製药和生物技术行业设计和製造产品的需求呈指数级增长。

mRNA 治疗药物合约开发和製造机构的市场报告亮点

  • 2023年病毒疫苗领域将以100.00%的份额占据市场主导地位。该行业的成长归因于治疗病毒感染（COVID-19）的各种疫苗的供应和推出的增加。
  • 由于感染疾病率不断上升、mRNA疫苗相对于传统疫苗的多项优势、新的临床研究和管道分析以及製药公司和市场占有率之间的生产合作不断增加，感染疾病领域将在2023年成为最大的领域。
  • 生技公司的最终用途领域占据市场主导地位，到2023年将占超过60.00%的份额。该细分市场的成长是由策略性倡议的增加所推动的，例如与 CDMO 建立 mRNA 疫苗生产的伙伴关係和合作。
  • 预计2024年至2030年亚太地区的成长率将达到10.83%，是最快的。随着印度和中国等开发中国家的製药公司和受託製造厂商的数量不断增加，亚太地区可能在不久的将来超过欧洲和北美。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章 mRNA 治疗合约开发与製造组织 (CDMO) 市场：变数、趋势、范围

  • 市场体系展望
  • 市场动态
  • mRNA 治疗合约开发与製造组织 (CDMO) 市场：分析工具
  • COVID-19 影响分析

第四章 mRNA 治疗药物合约开发与製造组织 (CDMO) 市场：按应用分析

  • mRNA 治疗药物合约开发和製造组织 (CDMO) 市场（按应用领域）：要点
  • mRNA治疗药物合约开发与製造组织（CDMO）市场：应用变化分析
  • 按用途
  • 病毒疫苗
  • 蛋白质替代疗法
  • 癌症免疫治疗

第五章 mRNA 治疗药物合约开发与製造组织（CDMO）市场：按适应症分析

  • mRNA 治疗药物合约开发和製造组织 (CDMO) 市场，按适应症细分：要点
  • mRNA治疗药物合约开发与製造组织（CDMO）市场：适应症变异分析
  • 按指示
  • 感染疾病
  • 代谢和遗传疾病
  • 心臟和脑血管疾病

第六章 mRNA 治疗药物合约开发和製造组织 (CDMO) 市场：最终用途分析

  • 按最终用途细分的 mRNA 治疗合约开发和製造组织 (CDMO) 市场：要点
  • mRNA 治疗合约开发与製造组织 (CDMO) 市场：最终用途变异分析
  • 按最终用途
  • 生技公司
  • 製药公司
  • 政府及学术研究机构

第 7 章 mRNA 治疗药物合约开发与製造组织（CDMO）市场：区域分析

  • 按区域细分的 mRNA 治疗合约开发和製造组织 (CDMO) 市场：要点
  • 2023 年和 2030 年 mRNA 治疗合约开发和製造组织 (CDMO)市场占有率分析
  • 按地区
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第8章 mRNA治疗药物合约开发与製造组织（CDMO）市场：竞争格局

  • 市场参与企业分类
  • 2022/2023年市场情势分析（热图分析）
  • 公司简介
  • 供应商情况
  • 2023年主要企业市场占有率分析
  • Danaher (Aldevron)
  • Biomay AG
  • Bio-Synthesis, Inc.
  • eTheRNA
  • Kaneka Eurogentec SA
  • TriLink BioTechnologies
  • ApexBio Technology
  • BioNTech SE
  • BioCina
  • Lonza
  • Recipharm AB
  • Novo Holdings (Catalent, Inc.)
  • Samsung Biologics
Product Code: GVR-4-68040-083-7

mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth & Trends:

The global mRNA therapeutics contract development & manufacturing organization market size is expected to reach USD 8.35 billion by 2030, registering a CAGR of 11.28% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market's growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.

The R&D spending was driven by increased clinical manufacturing activities, with the company's Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights:

  • The viral vaccines segment dominated the market with a share of 100.00% in 2023. Growth in the segment can be attributed to the rising availability and launch of various vaccines for the treatment of viral infection (COVID-19)
  • The infectious diseases segment held the largest market share in 2023 due to the growing incidence of infectious diseases, several advantages of mRNA vaccine over conventional vaccines, emerging clinical studies & pipeline analysis, and increasing collaboration between pharmaceutical companies & CDMO for production
  • The biotech companies end-use segment dominated the market and accounted for a share of more than 60.00% in 2023. The segment growth is driven by increasing strategic initiatives, such as partnerships & collaborations with CDMOs, to manufacture mRNA vaccines
  • Asia Pacific is expected to register the fastest growth rate of 10.83% from 2024 to 2030. Due to the rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Regional Scope
  • 1.2 Estimates And Forecast Timeline
  • 1.3 Market Definition
  • 1.4 Research Methodology
  • 1.5 Information Procurement
    • 1.5.1 Information Analysis
    • 1.5.2 Market Formulation & Data Visualization
    • 1.5.3 Data Validation & Publishing
  • 1.6 Research Scope And Assumptions
    • 1.6.1 Commodity Flow Analysis
    • 1.6.2 Top Down Market Estimation
    • 1.6.3 Region/Country Based Segment Share Calculation.
    • 1.6.4 Multivariate Analysis
    • 1.6.5 Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: CAGR Calculation
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
      • 3.1.2.1 Global Recombinant Protein Therapeutics CDMO Market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Rapid Adoption Of Mrna In Vaccine Development
      • 3.2.1.2 Multiple Research Efforts On Mrna Therapeutics
      • 3.2.1.3 Major Funding For Mrna Research
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Availability of Low-cost Substitute Therapies
      • 3.2.2.2 High Research Cost
  • 3.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Pestel Analysis
  • 3.4 COVID-19 Impact Analysis

Chapter 4 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Analysis

  • 4.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Application Segment: Key Takeaways
  • 4.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Movement Analysis
  • 4.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Application (USD Million)
  • 4.4 Viral Vaccines
    • 4.4.1 Viral Vaccines Market, 2018 - 2030 (USD Million)
  • 4.5 Protein Replacement Therapies
    • 4.5.1 Protein Replacement Therapies Market, 2018 - 2030 (USD Million)
  • 4.6 Cancer Immunotherapies
    • 4.6.1 Cancer Immunotherapies Market, 2018 - 2030 (USD Million)

Chapter 5 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Analysis

  • 5.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Indication Segment: Key Takeaways
  • 5.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Movement Analysis
  • 5.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Indication (USD Million)
  • 5.4 Infectious Diseases
    • 5.4.1 Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 5.5 Metabolic & Genetic Diseases
    • 5.5.1 Metabolic & Genetic Diseases Market, 2018 - 2030 (USD Million)
  • 5.6 Cardiovascular & Cerebrovascular Diseases
    • 5.6.1 Cardiovascular & Cerebrovascular Diseases Market, 2018 - 2030 (USD Million)

Chapter 6 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Analysis

  • 6.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by End-use Segment: Key Takeaways
  • 6.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Movement Analysis
  • 6.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by End-use (USD Million)
  • 6.4 Biotech Companies
    • 6.4.1 Biotech Companies Market, 2018 - 2030 (USD Million)
  • 6.5 Pharmaceutical Companies
    • 6.5.1 Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 6.6 Government & Academic Research Institutes
    • 6.6.1 Government & Academic Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 7 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Regional Analysis

  • 7.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Regional Segment: Key Takeaways
  • 7.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Share Analysis, 2023 & 2030
  • 7.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Estimates and Forecast, by Region (USD Million)
  • 7.4 North America
    • 7.4.1 North America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.4.2 U.S.
      • 7.4.2.1 Key Country Dynamics
      • 7.4.2.2 Competitive Scenario
      • 7.4.2.3 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.4.3 Canada
      • 7.4.3.1 Key Country Dynamics
      • 7.4.3.2 Competitive Scenario
      • 7.4.3.3 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
  • 7.5 Europe
    • 7.5.1 Europe Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.2 UK
      • 7.5.2.1 Key Country Dynamics
      • 7.5.2.2 Competitive Scenario
      • 7.5.2.3 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.3 Germany
      • 7.5.3.1 Key Country Dynamics
      • 7.5.3.2 Competitive Scenario
      • 7.5.3.3 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.4 France
      • 7.5.4.1 Key Country Dynamics
      • 7.5.4.2 Competitive Scenario
      • 7.5.4.3 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.5 Italy
      • 7.5.5.1 Key Country Dynamics
      • 7.5.5.2 Competitive Scenario
      • 7.5.5.3 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.6 Spain
      • 7.5.6.1 Key Country Dynamics
      • 7.5.6.2 Competitive Scenario
      • 7.5.6.3 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.7 Denmark
      • 7.5.7.1 Key Country Dynamics
      • 7.5.7.2 Competitive Scenario
      • 7.5.7.3 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.8 Sweden
      • 7.5.8.1 Competitive Scenario
      • 7.5.8.2 Key Country Dynamics
      • 7.5.8.3 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.5.9 Norway
      • 7.5.9.1 Key Country Dynamics
      • 7.5.9.2 Competitive Scenario
      • 7.5.9.3 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
  • 7.6 Asia Pacific
    • 7.6.1 Asia Pacific Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (Usd Million
    • 7.6.2 Japan
      • 7.6.2.1 Key Country Dynamics
      • 7.6.2.2 Competitive Scenario
      • 7.6.2.3 Japan Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.3 China
      • 7.6.3.1 Key Country Dynamics
      • 7.6.3.2 Competitive Scenario
      • 7.6.3.3 China Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.4 India
      • 7.6.4.1 Key Country Dynamics
      • 7.6.4.2 Competitive Scenario
      • 7.6.4.3 India Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.5 Australia
      • 7.6.5.1 Key Country Dynamics
      • 7.6.5.2 Competitive Scenario
      • 7.6.5.3 Australia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.6 South Korea
      • 7.6.6.1 Key Country Dynamics
      • 7.6.6.2 Competitive Scenario
      • 7.6.6.3 South Korea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.6.7 Indonesia
      • 7.6.7.1 Key Country Dynamics
      • 7.6.7.2 Competitive Scenario
      • 7.6.7.3 Indonesia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
  • 7.7 Latin America
    • 7.7.1 Latin America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.7.2 Brazil
      • 7.7.2.1 Key Country Dynamics
      • 7.7.2.2 Competitive Scenario
      • 7.7.2.3 Brazil Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.7.3 Mexico
      • 7.7.3.1 Key Country Dynamics
      • 7.7.3.2 Competitive Scenario
      • 7.7.3.3 Mexico Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.7.4 Argentina
      • 7.7.4.1 Key Country Dynamics
      • 7.7.4.2 Competitive Scenario
      • 7.7.4.3 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
  • 7.8 MEA
    • 7.8.1 Mea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.8.2 South Africa
      • 7.8.2.1 Key Country Dynamics
      • 7.8.2.2 Competitive Scenario
    • 7.8.3 Saudi Arabia
      • 7.8.3.1 Key Country Dynamics
      • 7.8.3.2 Competitive Scenario
      • 7.8.3.3 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.8.4 UAE
      • 7.8.4.1 Key Country Dynamics
      • 7.8.4.2 Competitive Scenario
      • 7.8.4.3 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)
    • 7.8.5 Kuwait
      • 7.8.5.1 Key Country Dynamics
      • 7.8.5.2 Competitive Scenario
      • 7.8.5.3 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021 - 2030 (USD Million)

Chapter 8 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Market Position Analysis, 2022/2023 (Heat Map Analysis)
  • 8.3. Company Profiles
    • 8.3.1. Strategy Mapping
    • 8.3.2. Service Launches
    • 8.3.3. Acquisition
    • 8.3.4. Partnerships/Agreements/Collaboration
    • 8.3.5. Expansions
  • 8.4. Vendor Landscape
    • 8.4.1. Key company market share analysis, 2023
    • 8.4.2. Danaher (Aldevron)
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product/service benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Biomay AG
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product/service benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Bio-Synthesis, Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product/service benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. eTheRNA
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product/service benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Kaneka Eurogentec S.A.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product/service benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. TriLink BioTechnologies
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product/service benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. ApexBio Technology
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product/service benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. BioNTech SE
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product/service benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. BioCina
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product/service benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Lonza
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product/service benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Recipharm AB
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product/service benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Novo Holdings (Catalent, Inc.)
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Product/service benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. Samsung Biologics
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Product/service benchmarking
      • 8.4.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 5 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 10 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 14 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 17 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 18 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 20 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 23 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 24 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 26 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 29 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 32 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 35 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 38 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 39 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 45 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 46 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 48 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 49 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 51 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 52 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 54 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 55 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 57 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 60 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 64 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 65 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 67 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 68 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 70 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 71 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 73 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 74 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 78 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 80 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 81 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 86 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 87 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018 - 2030 (USD Million)
  • Table 89 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018 - 2030 (USD Million)
  • Table 90 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 mRNA therapeutics contract development & manufacturing organization (CDMO) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Data analysis models
  • Fig. 5 Market formulation and validation
  • Fig. 6 Data validating & publishing
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook, 2023 (USD Billion)
  • Fig. 13 Ancillary market outlook, 2023 (USD Billion)
  • Fig. 14 mRNA therapeutics contract development & manufacturing organization (CDMO) market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTEL analysis
  • Fig. 17 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Application outlook and key takeaways
  • Fig. 18 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Application movement analysis
  • Fig. 19 Viral vaccines market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 20 Protein replacement therapies market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 21 Cancer immunotherapies market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 22 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Indication outlook and key takeaways
  • Fig. 23 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Indication movement analysis
  • Fig. 24 Infectious diseases market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 25 Metabolic & genetic diseases market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 26 Cardiovascular & cerebrovascular diseases market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 27 mRNA therapeutics contract development & manufacturing organization (CDMO) market: End use outlook and key takeaways
  • Fig. 28 mRNA therapeutics contract development & manufacturing organization (CDMO) market: End use movement analysis
  • Fig. 29 Biotech companies market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 30 Pharmaceutical companies market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 31 Government & academic research institutes market estimates and forecast, 2021 - 2030 (USD Million)
  • Fig. 32 Regional market: Key takeaways
  • Fig. 33 Regional outlook, 2023 & 2030
  • Fig. 34 Regional outlook, 2023 & 2030
  • Fig. 35 North America mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 U.S. mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Canada mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 40 Europe mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 UK mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Germany mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 France mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Italy mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Spain mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Denmark mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Sweden mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Norway mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 57 Asia Pacific mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Japan mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 China mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 India mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Australia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 South Korea mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Indonesia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 70 Latin America mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Brazil mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Mexico mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Argentina mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 77 MEA mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Africa mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Saudi Arabia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 UAE mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Kuwait mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021 - 2030 (USD Million)
  • Fig. 86 Market participant categorization
  • Fig. 87 Heat map analysis
  • Fig. 88 Strategy mapping